Cytori Therapeutics

Cytori Therapeutics, Inc. is dedicated to developing and delivering innovative cell-based therapies to improve the quality and length of life. We are a global, public company engaged in the development and commercialization of stem and regenerative cell therapies for the treatment of cardiovascular disease, reconstructive surgery and other serious, chronic, and life threatening conditions.

Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
1996
Size (employees)
80 (est)
Website
cytori.com
Cytori Therapeutics was founded in 1996 and is headquartered in San Diego, US

Cytori Therapeutics Office Locations

Cytori Therapeutics has offices in San Diego, Flintshire and Minato-ku
San Diego, US (HQ)
3020 Callan Rd

Cytori Therapeutics Data and Metrics

Cytori Therapeutics Financial Metrics

Cytori Therapeutics's revenue was reported to be $4.7 m in FY, 2016 which is a 4% decrease from the previous period.
USD

Revenue (FY, 2016)

4.7 m

Revenue growth (FY, 2015 - FY, 2016), %

(4%)

Gross profit (FY, 2016)

1.9 m

Gross profit margin (FY, 2016), %

42%

Net income (FY, 2016)

(22 m)

EBIT (FY, 2016)

(19.7 m)

Market capitalization (20-Jul-2017)

36.4 m

Closing share price (20-Jul-2017)

1.1

Cash (31-Dec-2016)

12.6 m
Cytori Therapeutics's current market capitalization is $36.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

7.1 m5 m4.8 m4.7 m

Revenue growth, %

(30%)(2%)(4%)

Cost of goods sold

3.4 m2.9 m3.2 m2.7 m

Gross profit

3.7 m2 m1.7 m1.9 m

Gross profit Margin, %

52%41%34%42%

Sales and marketing expense

9 m6.4 m2.7 m3.6 m

R&D expense

17.1 m15.1 m19 m16.2 m

General and administrative expense

16 m16 m9.8 m8.6 m

Operating expense total

39.5 m37.1 m23.8 m28.4 m

EBIT

(30.7 m)(32.4 m)(15.3 m)(19.7 m)

EBIT margin, %

(431%)(655%)(316%)(423%)

Interest expense

3.4 m4.4 m3.4 m2.6 m

Interest income

4 k6 k9 k19 k

Net Income

(26.2 m)(37.4 m)(18.7 m)(22 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

15.5 m14.6 m14.3 m12.6 m

Inventories

3.7 m

Current Assets

24.6 m21.7 m21.2 m18.7 m

PP&E

1.1 m1.6 m1.6 m1.2 m

Goodwill

3.9 m3.9 m3.9 m3.9 m

Total Assets

42.1 m38.7 m37.7 m34.6 m

Accounts Payable

6.1 m5.5 m6.7 m5.9 m

Current Liabilities

14.9 m15.9 m8.4 m12.5 m

Total Liabilities

23.6 m

Additional Paid-in Capital

303.7 m331.8 m368 m388.8 m

Retained Earnings

(300.9 m)(338.3 m)(357 m)(379.1 m)

Total Equity

3.1 m11 m

Financial Leverage

13.4 x3.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(26.2 m)(37.4 m)(18.7 m)(22 m)

Depreciation and Amortization

1.6 m779 k1.1 m1.2 m

Accounts Receivable

(1.2 m)2.1 m328 k(179 k)

Inventories

(459 k)(815 k)490 k471 k

Accounts Payable

(409 k)(1.1 m)1 m(673 k)

Cash From Operating Activities

(34.6 m)(30.3 m)(20.5 m)(19.5 m)

Purchases of PP&E

(519 k)(764 k)(611 k)(67 k)

Cash From Investing Activities

3.7 m(1.3 m)(613 k)64 k

Dividends Paid

(75 k)

Cash From Financing Activities

20.8 m30.9 m20.8 m17.6 m

Interest Paid

2.3 m2.6 m2 m1.6 m
Y, 2016

Financial Leverage

3.2 x

Cytori Therapeutics Market Value History

Cytori Therapeutics Online and Social Media Presence

Cytori Therapeutics News and Updates

Cytori Therapeutics Company Life and Culture

You may also be interested in